Ausgewählte Publikationen

Pastore F,Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring‐Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD and Hoster E.

Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia.

J Clin Oncol. 2014 Apr 7. [Epub ahead of print]

Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K* and Bohlander SK*. (*equal contribution)

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Blood. 2012; 120, 395‐403

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring‐Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W and Spiekermann K.

The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype.

Blood. 2012; 119, 4383‐4386

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Buchner T, Wormann B, Braess J, Hiddemann W, Bohlander SK and Spiekermann K.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Journal of Clinical Oncology. 2010; 28, 570‐577.

Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T and Müller‐Tidow C.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web‐based application for prediction of outcomes.

Lancet; 2010; 376, 2000‐2008.

Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, Fiegl M, Kern W, Buske C, Bohlander S, Heinecke A, Baurmann H, Beelen DW, Berdel WE, Büchner T, Hiddemann W.

Dose‐dense induction with sequential high‐dose cytarabine and mitoxantone (S‐HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Blood. 2009 Apr 23;113(17):3903‐10.

Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K.

CBL exon 8/9 mutants autoactivate the FLT3 pathway and cluster in CBF/11q deletion AML/MDS subtypes.

Clin Can Res. 2009; 15(7):2238-47.

Vempati S, Reindl C, Kaza SK, Kern R, Malamoussi T, Dugas M, Mellert G, Schnittger S, Hiddemann W, Spiekermann K.

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.

Blood. 2007; 110(2):686-94.

Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, Hopfner KP, Hiddemann W, Spiekermann K

Point mutations found in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML

Blood. 2006; 107:3700-3707.

Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, Hiddemann W, Spiekermann K.

FLT3‐ITDTKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl‐x(L).

Blood. 2005; 105: 3679‐3685.

Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla‐Martinez L, Bohlander SK, Feuring‐Buske M, Buske C

The AML1‐ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.

J Clin Invest. 2005 Aug;115(8):2159‐68

Bagrintseva, K., R. Schwab, T.M. Kohl, S. Schnittger, S. Eichenlaub, J.W. Ellwart, W. Hiddemann, and K. Spiekermann.

Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3‐ITD‐transformed hematopoietic cells.

Blood. 2004; 103:2266‐2275.

Spiekermann, K., R.J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske, S. Schnittger, L.M. Kelly, D.G. Gilliland, and W. Hiddemann.

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML‐derived cell lines expressing a constitutively activated FLT3.

Blood. 2003; 101:1494‐1504.

Alle in PubMed gelisteten Publikationen dieses Autors